Over 1 million patients benefited! Centralized procurement of coronary stents was implemented in 18 provinces, autonomous regions and municipalities
Today (January 1), the results of the national organization's centralized procurement of coronary stents were officially implemented in 18 provinces and cities including Beijing, Tianjin, and Liaoning. Patients in these places used the centralized coronary stents.
Centralized procurement of coronary stents was implemented in 18 provinces, autonomous regions and municipalities
The first batch of 18 provinces (regions) where the national organization of centralized procurement of coronary stents was implemented, including Beijing, Tianjin, Hebei, Liaoning, Jilin, Heilongjiang, Jiangsu, Zhejiang, Fujian, Shandong, Hunan, Guangdong, Hainan, Guizhou , Yunnan, Gansu, Qinghai, Xinjiang (including the Corps).
The local inventory of selected products in the first batch of 18 provinces, cities (regions), reached an average of 33% of the agreed purchase volume, which can meet the needs of medical institutions in the first month.
The remaining provinces will be implemented in January 2021, and strive to allow patients to use the coronary stent after the collection.
Chen Jinfu, deputy director of the National Medical Security Administration: For example, the patient should have a stent. He has installed two or three. This is an unreasonable medical behavior driven by interests. After this price space drops, he does not need to do more. It’s useless to do more. What’s more important is that he has the ability to pay for the patients who needed to use coronary stents. He couldn’t afford it before, but now he only has more than 700 yuan. He can do it. This way It has greatly expanded the accessibility of clinical medical services, so these are two benefits for the people.
National collection of coronary stents benefited more than 1 million patients
The national organization of centralized procurement of coronary stents produced the results of the selection in early November 2020. The average price of 10 selected varieties dropped from 13,000 yuan to about 700 yuan, a decrease of more than 90%. It is estimated that 10.9 billion yuan of medical insurance funds will be saved.
After the results of the selection were announced, various localities and departments carried out various preparations for implementation.
Before December 31, the drug regulatory department carried out a full-project supervision and inspection of all selected companies, urged the companies to implement the main responsibility for quality and safety, and ensure the quality and safety of selected coronary stents.
The health department promptly organizes medical institutions to sign purchase agreements, clarify production and distribution relationships, and strengthen the monitoring of medical institutions’ inventory.
The medical insurance department urges the selected companies to sell online at the selected price, and at the same time introduces a medical insurance payment policy to ensure that the reduced price of coronary stents can be used and reimbursed for patients.
In my country, about 1 million patients with coronary heart disease are implanted with heart stents each year. Patients can use the selected heart stents, which will greatly reduce the burden of medical treatment for patients.
Chen Jinfu, deputy director of the National Medical Security Administration: After the price is lowered, everyone is concerned about whether the company is cutting corners. In this regard, we have a complete system design.
First, the enterprise is the first person responsible for quality; second, there is quality assurance on the threshold of entering the recruitment and procurement; third, the company must have quality commitments during the participation in the recruitment process; fourth, the government has quality The most important aspect of the supervision of the company is that, in terms of its quality development and brand maintenance, companies will regard quality as their life.
(CCTV reporter Zhang Ping)